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Abstract
Background Studies have shown patient attitudes to be an
important predictor for health related behaviours including
medication adherence. It is less clear whether patient atti-
tudes are also associated with medication adherence among
patients with psychoses.
Method We conducted a systematic review and meta
analysis of the data of studies that tested the association of
attitude measures with medication adherence among
patients with psychoses. 14 studies conducted between
1980 and 2010 were included.
Results Results show a small to moderate mean weighted
effect size (r? = 0.25 and 0.26 for Pearson and Spearman
correlations, respectively).
Conclusions Theory based interventions that target
potentially modifiable attitude components are needed to
assess the relationship between positive patient attitudes
and adherence behaviours among patients with psychoses.
Keywords Medication adherence  Attitudes  Psychoses
Introduction
Failure to adhere to medication is an important issue
among all disease groups, with costly implications both for
the patient and health service providers. Among patients
with psychoses, non-adherence rates are particularly high,
with reports ranging from 20 to 89 % [1, 2]. It has been
proposed that patients with psychoses lack insight into their
illness, and that this influences adherence to medication
regimes [3]. Non-adherence to antipsychotic medication may
not only enhance distressing symptoms, and the likelihood
of relapse but also negatively influence the patients’ quality
of life and long-term prognosis [4]. Moreover, failure to
adhere to prescribed regimens may result in longer and more
frequent periods of inpatient care, leading to increases in the
overall cost of care [5].
The possibility that more positive patient attitudes
towards medication adherence are associated with better
adherence behaviours among various populations including
patients with psychoses [6] is of interest given that it may
be possible to intervene to change attitudes. There is also
increasing emphasis placed on patient-reported outcomes
(PROs) among patients with psychoses [7], suggesting that
a focus on individual’s cognitive representations may be
relevant to clinical treatment outcomes among this patient
population. This perspective coincides with various social
cognitive models (SCMs) such as the health belief model
(HBM) [8] and theory of planned behaviour (TPB) [9] that
assess various cognitive representations (beliefs or atti-
tudes) about health behaviours.
The term ‘social cognition models’ refers to a group of
similar theories that identify cognitive and affective factors
as the proximal determinants of behaviour. Key constructs
in the HBM include perceived susceptibility and perceived
severity with respect to a given health threat. Like the
HBM, the TPB assumes that individuals weigh up the costs
and benefits of possible future courses of action. The model
assumes that the intention or motivation to perform a
behaviour (such as medication adherence) is a function of
three determinants including attitude towards the behav-
iour. Attitudes reflect the person’s overall evaluation of
performing the behaviour and are based on beliefs
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concerning the likely consequences and evaluations of
those consequences of performing a particular behaviour.
These beliefs include those specified by the HBM. For
example, a patient who believes that taking their medica-
tion will lead to more positive (than negative) personal
consequences will hold a favourable attitude towards the
behaviour.
While relatively few studies have utilised social cogni-
tive theories among patients with psychoses (see [10, 11],
for exceptions) they have been applied successfully to
numerous health behaviours including adherence to medi-
cation regimes among patients with urinary tract infections
[12], diabetes [13], HIV or AIDS [14] and travellers in
malaria regions [15].
Among psychiatric populations, the self reported drug
attitude inventory (DAI; [16]), and the observer rating of
medication influence (ROMI; [17]) have been predomi-
nately utilised to assess patient attitudes towards adherence.
Like attitude constructs in the HBM [18] and the TPB [9],
these measures assess beliefs about medication adherence
including perceived benefits, costs and relapse prevention.
Additionally, the ROMI includes aspects of therapeutic
alliance, normative beliefs and barriers to treatment.
Patient attitudes towards medication adherence may
provide a potentially important target for intervention as
they are proposed to be potentially modifiable [9]. How-
ever, before the relevance of attitudes for adherence among
patients with psychoses can be established, research syn-
thesis is needed to examine (1) the size of the association
between attitudes and medication adherence behaviours
and (2) the generalisability of the findings across the rel-
evant studies.
In this review, systematic search and meta-analytic
techniques were employed to test the hypotheses that posi-
tive patient attitudes towards medication will be positively
correlated with adherence behaviours among patients with
psychoses. Additionally, study quality will be explored as a
moderator of the attitude/adherence association.
Method
Searches and inclusion criteria
A three-stage systematic search was undertaken to locate
primary research papers relevant to the review. Initial
search terms contained adjectives or derivatives of the
following 4 terms: ‘medication’ (e.g. neuroleptic or anti-
psychotic), ‘compliance’ (e.g. adherence), ‘attitudes’
(e.g. subjective response or health beliefs) and ‘psychosis’
(e.g. schizophrenia or schizo or psychosis) that were
combined using a series of Boolean and/or operators
and wildcards. These combinations were used to search
Medline, Psychinfo and Psych-articles databases between
1980 and 2010. Only English language journals were
considered.
Potentially relevant articles were exported into a refer-
ence citation manager where titles and abstracts were
screened (by MR) for relevance. At stage 2, studies were
included only if (a) at least 70 % of the sample were
diagnosed as having a psychotic disorder (including
schizophrenia, schizo-affective disorder and psychoses),
(b) a measure of attitude with established psychometric
properties was included (c) attitude was linked bivariately
to at least one measure of medication adherence. The effect
size r was used as it represents both the direction and
strength of associations. Where data was missing, authors
were contacted. Papers from which data were extracted are
marked with an asterisk in the reference section.
Data coding
The following data were coded from each primary article
including (a) reference details; (b) country; (c) sample size
and patient diagnoses; (d) attitude measure(s); (e) study
design and length of time to outcome; (f) adherence mea-
sure(s); (g) effect size estimate in r; (h) internal reliability
of the attitude measure(s); (i) internal reliability of the
adherence measure(s) where present. Following previous
research [19], Pearson and Spearman correlations were
analysed independently; the study details of which are
presented in Tables 1, 2, respectively.
In order to minimise bias resulting from statistically
dependent findings [19], global composite scores were
coded wherever available and no more than two associa-
tions were extracted from a single study. Where there were
more data available, the later outcome i.e. that measured
most distant to the attitude measure was extracted. When
different values other than r were reported, the following
effect size types were converted into r:t, F, X2 .
Quality criteria
Due to the problems of multiple testing, a global index of
study quality was developed. The following criteria and
coding were used to assess for each association the quality
of the study reporting it: the sample size (\30 = 0, C30
and \100 = 1, C100 = 2), study design (cross sec-
tional = 0 and prospective = 1), the conceptual validity of
the instrument used to measure attitude (confounded atti-
tude measure = 0, ‘pure’ attitude assessment = 1), valid-
ity of the adherence measure (no established scale = 0,
established scale = 1), reliability of adherence measure
(self reported, by patient or observer = 0, combination
of patient and observer self reports = 1, combination
of objective and self reported measures = 2, objective
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measure = 3), internal reliability of attitude and adherence
measures (internal consistency \0.70 or non reported
reliability = 0, internal reliability [0.70 = 1). When
adherence was measured objectively rather than self
reported, internal reliability was assumed to be to ade-
quate. Scores were summed across each item to create an
overall quality score, ranging from 0 to 9 with higher
scores indicating better study quality. Studies were then
allocated to one of three groups, i.e. low (0–3), medium
(4–6) and high quality (7–9), a distinction used in other
reviews [20].
Inter-rater reliability
All articles were coded by two independent researchers. An
initial agreement rate of 89 % across all judgments was
obtained and all disagreements were resolved through
discussion.
Analytic strategy
Hypotheses were examined in three analytic steps. First,
meta-analytic findings for the overall attitude effects were
calculated. Second, publication bias was assessed using
Duval and Tweedie’s trim-and-fill procedure [21]. Third,
study quality was explored as a moderator of the attitude/
adherence association.
Consistent with accumulating evidence, heterogeneity in
effect sizes was expected [22]. Thus, observed correlations
were pooled and corrected for sampling error using a
random effects model. The mean observed (r?) correlation
and corresponding confidence intervals were also calcu-
lated. Heterogeneity between scores was assessed using I2
and Q statistics. The Q statistic reflects the total amount of
variance in the meta analysis while the I2 value indexes the
proportion of variance that is due to between-study dif-
ferences and unlike the Q statistic, it is not sensitive to the
number of studies considered. I2 values range from 0 to
100 % and it has been suggested that values of 25, 50 and
75 % indicate low, moderate and higher heterogeneity,
respectively [23].
Publication of statistically significant results is more
probable [24] which increases the likelihood of type 1
errors (and an over estimation of the mean effect size) in
meta analysis. In order to examine this potential bias, we
applied Duval and Tweedie’s [21] ‘trim-and-fill’ procedure
which estimates the number of studies that may be missing
due to publication bias, and then imputes these missing
studies prior to re-calculating the attenuated effect size.
Plots of effect size against inverse standard errors around
the mean effect size estimate were used in these analyses.
For the moderation analyses, sub-group analysis was
performed by grouping the associations by study quality
and assessing heterogeneity between groups using the
Qbetween statistic within a random effects model.
Comprehensive Meta analysis, version 2.0 (Biostat;
Englewood, NJ, USA) was used for all analyses.
Results
At stage one, the search strategy yielded a total of 641
papers. After scanning abstracts and titles using the spec-
ified inclusion criteria, 111 papers were identified as rele-
vant and read in detail. The substantial exclusions at this
stage were due to a large number of studies that had not
assessed both attitudes towards medication and adherence
behaviours. 14 papers [10, 11, 25–36] of the 111 poten-
tially relevant papers were found to meet all inclusion
criteria and were included in the review. The search pro-
cess is summarised in Fig. 1.
The reported studies were conducted in Hong Kong,
Spain, Denmark, the Netherlands, the United Kingdom and
the United States. The percentage of patients with psy-
chosis varied between 71 and 100 %.
Data description
A total of 19 independent correlations were analysed. Of
these, 13 (N = 1,911) were Pearson correlations (r) while 6
were Spearman Rank-order coefficients (rs) (N = 780). Of
the Pearson correlations, 8 were coded as poor in quality
(N = 1,034) and 5 as moderate in quality (N = 877). There
were no associations coded as good in quality. Of the
Spearman correlations, 3 associations were coded as poor
in quality (N = 519), 2 as moderate in quality (N = 203)
and 1 as good in quality (N = 58).
Figures 2, 3 present the meta-analytic results for the
Pearson and Spearman correlations, respectively, and
include the study details, sample size (N), each study r, the
mean weighted (r?) and 95 % confidence intervals (CIs)
Overall attitude effect for Pearson’s correlations
The averaged corrected correlation between attitude and
adherence behaviours was r? = 0.25, (CIs = 0.18–0.32),
Q(12) 29.95, p \ 0.05. This represents a small-to-medium
effect size and as the confidence intervals did not include
zero, the null hypothesis was rejected. All of the effects
were positive in valence. The Q statistic, and an I2 statistic
of 51.90 % showed a moderate degree of heterogeneity in
the effect size across the studies, which indicated the
likelihood of moderators [37].
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Overall attitude effect for Spearman’s correlations
The averaged corrected correlation between attitude and
adherence behaviours was r? = 0.26, (CIs = 0.12–0.38],
Potentially relevant citations 
identified in PsycINFO. 
PsycARTICLES, and Medline 
between 1980-2010 (n =641)
Full text retrieved for more 
detailed evaluation: (n = 111) 
Studies included in the analysis: 
(n = 14) 
Citations excluded: (n = 530) 
• no standardised measure 
of attitude and/or 
adherence 
• non-English language 
articles 
• Non- diagnostic 
psychoses samples 
Studies excluded after full text 
retrieval (n = 97) 
• no standardised 
measurement of attitude 
and/or adherence 
• < 70% of sample  
diagnosed with 
psychoses 
• Relevant data not 
reported and unavailable 
from the author
Independent correlations (k) 
included in the analysis (k =19) 
• Pearson’s 
correlations, k=13  
• Spearman’s 
correlations, k=6 
Fig. 1 Search process of the
literature
Note : a = benefits;b = non-compliance items, 
Study and sample size Correlation and 95% CI
Agarwal et al., 1998 76
Donohoe et al., 2001 32
Haan et al., 2007 97
Kamali et al., 2001 66
Kapelowics et al.,2007 155
Kelly et al., 1987 107
Kelly et al., 1987a 107
Mutsatsa et al., 2003 101
Mutsatsa et al., 2003b 101
Quach et al., 2009 432
Quach et al., 2009b 432
Tsang et al, 2009b 119
Tsang et al., 2009 86
-1.00 -0.50 0.00 0.50 1.00
Pearson’s r
Fig. 2 Forest plot of the Pearson correlations (with 95 % confidence
intervals) between attitude and medication adherence
Study and sample size Correlation and 95% CI
Cabeza et al., 2000 60
Dolder et al., 2004 58
Fialko et al., 2008 277
Hayward et al., 1995 21
Kennedy et al., 2003 182
Kennedy et al., 2003a 182
-1.00 -0.50 0.00 0.50 1.00
Spearman’s r
Note.a = drug behaviour scale items 
Fig. 3 Forest plot of Spearman correlations (with 95 % confidence
intervals) between attitude and medication adherence
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Q(5) 15.35, p = 0.01. This represents a small-to-medium
effect size and as the confidence intervals did not include
zero, the null hypothesis was rejected. All of the effects
were positive in valence. The Q statistic, and an I2 statistic
of 67.43 % showed a substantial degree of heterogeneity in
the effect size across the studies, which indicated the
likelihood of moderators [37].
Publication bias
For the overall analyses we found no evidence of publi-
cation bias. A single missing effect was identified for the
Spearman correlations. However, adjusting for the missing
study did not significantly alter the mean effect size
(r?= 0.23, CIs = 0.09–0.36).
Moderator analysis
For the Pearson correlations, sub-group analysis indicated
that the between-study heterogeneity was not due to study
quality, Qbetween = 1.11 (1), p = 0.26 (for studies coded as
medium r? = 0.29, CIs = 0.19–38; for studies coded as
poor, r? = 0.22, CIs = 0.13–0.30). There were not enough
studies using Spearman correlations to explore study
quality as a moderator.
Discussion
We systematically reviewed and meta analysed the empiri-
cal evidence on attitudes towards medication adherence
and medication adherence behaviours among patients with
psychoses. A positive relationship of a small to moderate
magnitude was observed. However, this should be inter-
preted in the light of the methodological problems assessing
both adherence and attitudes. Study quality as a moderator
did not account for the significant heterogeneity between
studies. The review has various limitations. Because of the
small number of studies we were unable to conduct uni-
variate moderator analysis, which may have explained some
of the heterogeneity between studies. Nonetheless, a global
index of study quality did not moderate the attitude/adher-
ence combination across the relevant studies suggesting that
theoretical moderators may be operating. For example, side-
effect profiles may moderate the attitude/adherence associ-
ation with more noxious medications reducing adherence. It
is also important to consider stage of illness (recent onset vs.
chronic), patient’s psychotic state (active vs. remission) in
addition to a number of individual characteristics such as
length of illness, substance abuse, gender, ethnicity and
social economic status.
The remaining limitations reflect the different ways
in which attitudes and adherence are measured and
methodological shortcomings of the included studies, only
one of which met the defined criteria for a high quality
study. There is a considerable body of work showing that
measuring attitudes is problematic in some respects.
Measuring an attitude rests on the idea that there is one
stable underlying concept that can be identified as an
attitude towards a particular thing, which may not always
be the case. Moreover, there are different conceptualisa-
tions of attitudes towards medication operationalised in the
various scales used to measure medication attitude in the
primary studies reviewed herein. For example, the Medi-
cation Adherence Rating Scale includes items on behav-
ioural aspects (forgetting to take medication) and side
effects (feeling tired and sluggish). Both the Drug Attitudes
Inventory and the Rating of Medication Influences (ROMI)
include items relating to subjective experience while on
medication. In addition, the ROMI also includes aspects of
therapeutic alliance and self-efficacy which although rele-
vant, may be distinctive concepts to patient attitudes. These
considerable differences should be kept in mind when
interpreting the current findings.
The measurement of adherence is known to be prob-
lematic. There is often little agreement about how to define
and measure adherence to antipsychotics [2]. Most of the
included studies relied on self reports of adherence from
either the clinician or the patient, with only one employing
an objective measure of adherence. Agreement between
different raters can be low. This means that there is likely
to be considerable variance in what is being assessed. With
respect to psychometric properties of the attitude and
adherence scales, internal reliability coefficients were
reported in 4 studies for attitudes and a single study for
adherence.
The finding that attitudes are small to moderately posi-
tively related to adherence behaviour among patients with
psychoses is consistent with the findings in other domains
and populations, both in direction and size [15] indicating
that the patient decision making process is relevant
to clinical outcomes among patients with severe mental
illness. Thus, despite the specific illness characteristics
typically associated with psychoses (e.g. lack of insight)
the relationship between attitudes and medication adher-
ence may be comparable to other populations without any
mental illness. This finding substantiates recent qualitative
reviews [6] and adds to these by providing mean effect size
estimates and indexes of heterogeneity. Importantly, this
result is consistent with the growing body of evidence
indicating that subjective patient reports are associated
with clinical outcomes among patients with psychoses [7].
The finding that patient attitudes towards medication
adherence are positively related to adherence is consistent
with SCMs such as the TPB. The TPB proposes that atti-
tudes predict behavioural intentions, which reflect an
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individual’s motivation to engage in the behaviour. Fol-
lowing this, patient motivation is the presumed mechanism
that accounts for adherence behaviours among patients
with psychoses. Nonetheless, the TPB also acknowledges
that positive intentions to engage in a behaviour is not
always sufficient and self regulatory factors influence the
capacity to translate intentions into action. Thus, self reg-
ulatory skills such as setting specific plants to implement
goals may be needed.
Theoretical models are rarely tested in research on
medication adherence among psychiatric populations.
This is limiting as theoretical models like the TPB not
only specify the causal mechanism of behaviour change
but also facilitate the conceptualisation of distinct but
closely related constructs [38]. For example, the TPB
identifies normative beliefs, and perceptions of control as
distinct antecedents of behavioural intention. The current
findings indicate that SCMs such as the TPB may be
relevant to patients with psychoses although the measures
may need to be adapted. Models such as the TPB are often
attractive for researchers as additional constructs can be
added when they explain variation over and above those
already specified in the model. Thus, other constructs (e.g.
therapeutic alliance) if found to be relevant could be
included.
If these results are replicated in methodologically more
sophisticated studies, they suggest that interventions target-
ing patient attitudes could be developed. An example is the
leaflet-like intervention [39] that included persuasive com-
munication targeting the formation of positive attitudes by
highlighting the advantages of drinking within daily limits
(e.g. fewer headaches and hangovers and lower risk of liver
disease). Similar interventions could be developed and
evaluated in the context of medication adherence and could
have direct implications for healthcare policy and clinical
practise. The development of interventions is important
because, unlike correlation studies, where only associations
are tested, causal statements about the direction of the
association can be made in addition to assessments of clin-
ical relevance. A recently developed taxonomy of behaviour
change techniques [38] could facilitate the selection of
appropriate technique(s) for targeting attitude change and
subsequent medication adherence.
This review underlines the need for methodologically
more rigorous research and points to at least three require-
ments for future research in the area. First, attitude and
adherence should be assessed with accurate instruments that
have been shown to be valid measures among patients with
psychosis. Second, research should consider the role of
attitudes after consideration of other relevant constructs
(e.g. therapeutic relationship), in addition to potential
mediating and moderating factors using a theoretical
framework such as the TPB. Third, interventions designed to
target and improve patient attitudes towards medication
adherence should be developed and evaluated.
Medication adherence is a complex issue particularly
among patients with psychoses. The evidence reviewed
here identifies patient attitudes as central to adherence.
Specifically, among patients with psychoses, subjective
evaluations of medication adherence appear to be posi-
tively related to adherence behaviours. Rational decision
making models such as the TPB could therefore be tested
empirically among patients with psychoses.
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